{'52WeekChange': -0.097408354,
 'SandP52WeekChange': None,
 'address1': '2155 Park Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 11.16,
 'askSize': 1000,
 'averageDailyVolume10Day': 606475,
 'averageVolume': 420036,
 'averageVolume10days': 606475,
 'beta': 1.338775,
 'beta3Year': None,
 'bid': 9.75,
 'bidSize': 1000,
 'bookValue': 1.759,
 'category': None,
 'circulatingSupply': None,
 'city': 'Palo Alto',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 10.45,
 'dayLow': 9.89,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.213,
 'enterpriseToRevenue': None,
 'enterpriseValue': 210789424,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 618 1621',
 'fiftyDayAverage': 10.104571,
 'fiftyTwoWeekHigh': 15.82,
 'fiftyTwoWeekLow': 4.55,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 20840662,
 'forwardEps': -1.87,
 'forwardPE': -5.465241,
 'fromCurrency': None,
 'fullTimeEmployees': 27,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.016970001,
 'heldPercentInstitutions': 0.85047996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1458691200,
 'lastSplitFactor': '1:15',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/eigerbio.com',
 'longBusinessSummary': 'Eiger BioPharmaceuticals, Inc., a late-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of targeted therapies for rare '
                        'and ultra-rare diseases in the United States and '
                        'internationally. Its lead product candidate is '
                        'Lonafarnib, an orally bioavailable, small molecule, '
                        'which is in Phase 3 clinical trial to treat hepatitis '
                        "delta virus (HDV) infection. The company's product "
                        'candidate also include Lambda, which targets type III '
                        'interferon receptors that is in Phase 2 clinical '
                        'trial; Lonafarnib for the treatment of progeria and '
                        'progeroid laminopathies; and Avexitide that has '
                        'completed phase 2 clinical trial to treat '
                        'post-bariatric hypoglycemia, as well as in phase 2 '
                        'clinical trial for the treatment of congenital '
                        'hyperinsulinism. The company is headquartered in Palo '
                        'Alto, California.',
 'longName': 'Eiger BioPharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 256076416,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_52776077',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68302000,
 'nextFiscalYearEnd': 1640908800,
 'open': 10,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 272 6138',
 'previousClose': 10.1,
 'priceHint': 2,
 'priceToBook': 5.8101196,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 10.45,
 'regularMarketDayLow': 9.89,
 'regularMarketOpen': 10,
 'regularMarketPreviousClose': 10.1,
 'regularMarketPrice': 10,
 'regularMarketVolume': 605557,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 25056400,
 'sharesPercentSharesOut': 0.0275,
 'sharesShort': 689974,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 647591,
 'shortName': 'Eiger BioPharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.028199999,
 'shortRatio': 1.96,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'EIGR',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.832,
 'twoHundredDayAverage': 10.0742445,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'f40195ae-deeb-3177-beb3-ef4809e78599',
 'volume': 605557,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.eigerbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94306'}